Last Posted: Aug 09, 2018
- [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Niibe H et al. Nihon Gan Chiryo Gakkai shi 1985 Jun 20(5) 994-1001 - Machine Learning
NIH Catalyst, July 2018 - Cancer Scientists Have Ignored African DNA in the Search for Cures
J Wapner, Newsweek, July 2018 - Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
Rogeri Caroline Domingues et al. Gynecologic oncology 2018 Jun - Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Ngoi N Y L et al. Gynecologic oncology reports 2018 May 241-5 - Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers
NCI, May 2018 - Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi Andrew et al. The oncologist 2017 Jun 22(6) 631-637 - Cancer disparities
- Personalized cancer screening: helping primary care rise to the challenge.
Selby Kevin et al. Public health reviews 2018 394 - Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.
Dinh Tuan A et al. Cancer prevention research (Philadelphia, Pa.) 2011 Jan 4(1) 9-22
No hay comentarios:
Publicar un comentario